E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Pancreatic exocrine insufficiency in diabetes type II |
Insuficiencia pancreática exocrina en diabetes tipo 2 |
|
E.1.1.1 | Medical condition in easily understood language |
maldigestion of dietary macronutrients (pancreas not producing enough enzymes for digestion of fat, sugars and proteins) in diabetes type II |
Mala digestion de macronutrients de la dieta (el páncreas no produce suficientes enzimas para la digestión de la grasa, azúcares y proteínas) en diabetes tipo 2 |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the effect of Creon 25000 versus placebo on fat digestion as measured by the 13C Mixed Triglycerides Breath Test (MTBT) in patients with pancreatic exocrine insufficiency (PEI) and type 2 diabetes mellitus (DM). |
Evaluar el efecto sobre la digestión de grasas de Kreon 25000 frente a placebo evaluada por medio del test de aliento con 13C triglicéridos mixtos (MTBT, mixed triglycerides breath test) en pacientes con insuficiencia pancreática exocrina (PEI, pancreatic exocrine insufficiency) y diabetes mellitus (DM) de tipo 2. |
|
E.2.2 | Secondary objectives of the trial |
Secondary Objectives: To assess the effect of Creon on nutritional parameters (fat soluble vitamins (D and E), retinol-binding protein, albumin, pre-albumin, magnesium, calcium), HbA1c, quality of life assessed via a questionnaire (Gastrointestinal-Quality of Life Index, GIQLI), Clinical Global Impression of Disease Symptoms, clinical symptomatology (stool frequency, stool consistency, abdominal pain, flatulence), and use of anti-diabetic medication. Safety and Tolerability Objectives: To evaluate the safety and tolerability of Creon in type 2 DM patients with PEI by collecting treatment-emergent adverse events (TEAE), vital signs (incl. body weight and BMI), physical examination and routine safety laboratory. |
Objetivos Secundarios: Evaluar el efecto de Kreon en parámetros nutricionales (vitaminas liposolubles [D y E], proteína transportadora de retinol, albúmina, pre-albúmina, magnesio y calcio), HbA1c, calidad de vida evaluada con el cuestionario GIQLI (Gastrointestinal Quality of Life Index), Impresión Clínica Global de los Síntomas de la Enfermedad, sintomatología clínica (frecuencia de las deposiciones, consistencia de las heces, dolor abdominal y flatulencia), y uso de medicación antidiabética. Objetivos de Seguridad y Tolerabilidad: Evaluar la seguridad y tolerabilidad de Kreon en pacientes con DM tipo 2 con PEI por medio de los acontecimientos adversos emergentes (TEAE, treatment emergent adverse events), constantes vitales (incluyendo el peso corporal y el índice de masa corporal [IMC]), exploración física y pruebas rutinarias de laboratorio |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
? Signed Informed Consent ? BMI < 30 kg/m2 ? History of type 2 diabetes mellitus as confirmed by: ? onset of diabetes after 30 years of age and ? no insulin treatment in the first year after diagnosis ? Subjects on insulin treatment or on insulin treatment in combination with oral antidiabetics ? HbA1c > 6.5% in medical history within the last 6 months despite insulin treatment ? Not previously treated with any pancreatic enzyme supplementation ? FE-1 <100?g/g of stool ? 13C MTBT of <29% 13CO2-CRR |
? Consentimiento Informado Firmado. ? IMC < 30 kg/m2 ? Historia de diabetes mellitus tipo 2 confirmada por: ? inicio de la diabetes diagnosticada después de los 30 años y ? sin tratamiento con insulina en el primer año tras el diagnóstico ? Sujetos en tratamiento con insulina o en tratamiento con insulina en combinación con antidiabéticos orales. ? HbA1c > 6.5% en la historia clínica dentro de los 6 últimos meses a pesar del tratamiento con insulina. ? No tratado previamente con un suplemento de enzima pancreático. ? FE-1 < 100?g/g de heces ? 13C MTBT <29% 13CO2-CRR |
|
E.4 | Principal exclusion criteria |
? Treatment with systemic steroids for at least 3 weeks within past 6 months ? Patients with a known pancreatic exocrine insufficiency due to non-diabetic diseases, e.g., chronic pancreatitis, pancreatectomy, cystic fibrosis, celiac disease, shwachman-diamond syndrome, gastrectomy, etc. ? Known allergy to products of porcine origin ? Any type of malignancy involving digestive tract in the last 5 years ? Any type of gastrointestinal surgery (except appendectomy and gallbladder resection) ? Short bowel syndrome ? Hemochromatosis ? Any history of drug abuse including alcohol ? Positive urine pregnancy test; lactation; females of child-bearing potential who are not using either an oral hormonal contraceptive or an intrauterine device ? Severe allergy or any history of severe abnormal drug reaction ? Intake of an experimental drug within 4 weeks prior to entry into this study ? Suspected non-compliance or non-cooperation ? History of human immunodeficiency virus (HIV) infection |
? Tratamiento con esteroides sistémicos durante al menos 3 semanas en los últimos 6 meses. ? Pacientes con una insuficiencia pancreática exocrina conocida debida a enfermedades no diabéticas, p. ej., pancreatitis crónica, pancreatectomía, fibrosis quística, enfermedad celiaca, síndrome de shwachman-diamond, gastrectomía, etc. ? Alergia conocida a los productos de origen porcino. ? Algún tipo de tumor maligno en el tracto digestivo en los últimos 5 años. ? Cirugía gastrointestinal (excepto apendicetomía y resección de la vesícula biliar). ? Síndrome del intestino corto. ? Hemocromatosis ? Historia de abuso de drogas incluyendo el alcohol. ? Prueba positiva de embarazo en orina; lactancia; mujeres en edad fértil que no usen anticonceptivo hormonal oral o un dispositivo intrauterino. ? Alergia severa o historia de reacción severa al fármaco. ? Ingesta de un fármaco experimental dentro de las 4 semanas previas a la entrada del estudio. ? Sospecha de no cumplimiento o no cooperación. ? Historia de infección del virus de inmunodeficiencia humana (VIH). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy parameter will be the change from baseline to the end of the double-blind treatment in the 6-hour 13CO2?CRR as measured by the 13C MTBT. |
El parámetro principal de eficacia será el cambio desde basal al final del tratamiento doble ciego del 13CO2?CRR a las 6 horas calculado usando el 13C MTBT. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Change from baseline after 12 weeks of treatment |
Cambio desde basal después de 12 semanas de tratamiento |
|
E.5.2 | Secondary end point(s) |
? nutritional parameters (fat soluble vitamins (D and E), retinol-binding protein, albumin, pre-albumin, magnesium and calcium), ? HbA1c, ? quality of life (QoL) assessed via a questionnaire (GIQLI), ? Clinical Global Impression (CGI) of Disease Symptoms, ? clinical symptomatology (stool frequency, stool consistency, abdominal pain, and flatulence), ? Use of anti-diabetic medication (insulin and, if applicable, oral anti-diabetic medication). The safety and tolerability data collected during this study are vital signs, height, weight and BMI, safety laboratory values and adverse events. |
? Parámetros nutricionales: Niveles sanguíneos de vitaminas liposolubles (D y E), proteína transportadora de retinol, albúmina, pre-albúmina, magnesio y calcio), ? HbA1c, ? Calidad de vida (QoL) evaluada con el cuestionario GIQLI, ? Impresión Clínica Global de los Síntomas de la Enfermedad, ? Sintomatología clínica (frecuencia diaria de las deposiciones, consistencia de las heces, dolor abdominal y flatulencia) ? Utilización de medicación antidiabética (insulina y si procede, medicación oral antidiabética). Los datos de seguridad y tolerabilidad recogidos durante el estudio incluirán constantes vitales, altura, peso e IMC, valores de laboratorio de seguridad y acontecimientos adversos. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Secondary efficacy parameters are evaluated by the change from baseline to 12 week of treatment. Safety parameters are assessed throughout the study. |
Los parámetros secundarios de eficacia se evalúan por medio de su cambio a las 12 semanas de tratamiento respecto a basal. Los parámetros de seguridad se evalúan a lo largo de todo el estudio. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Última visita del último paciente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 2 |